# The Healthcare Pulse: April 10–17, 2026 > Podcast-sourced healthcare brief for April 10–17, 2026. The GLP-1 oral wars go live with Lilly's Foundayo launch, while M&A, the biotech rally, and a favorable Medicare Advantage rate reshape the sector. ## The Healthcare Pulse: Weekly Podcast Intelligence Brief ### Week of April 10–17, 2026 --- ```request-access variant: ghost heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` ## 1. This Week at a Glance The GLP-1 oral wars officially began this week as Eli Lilly's Foundayo hit pharmacy shelves on April 15, triggering a head-to-head rivalry with Novo Nordisk's oral Wegovy that will define the obesity market for years. Meanwhile, healthcare M&A reached a fever pitch. 7 deals totaling over $28B in upfront value landed in the past three weeks alone, and the biotech sector continued its stunning rally, with XBI up 8% YTD and 84% from its 52-week low. Against this backdrop, the managed care sector digested a far-better-than-expected 2.48% Medicare Advantage rate increase for 2027, sending UNH up 10% in a single session, while a 100% tariff announcement on pharmaceutical imports proved to be more bark than bite thanks to sweeping exemptions. --- ## 2. The People Driving the Conversation **Dr. Roderick Wong, RTW Investments.** Delivered the most bullish macro call on biotech: "This is the most exciting time in drug discovery in [the] couple dozen years... a lot of that exciting science is actually maturing. A good chunk is making it to the finish line... you're going to have this now wave of new commercially successful biotech companies, really of the size that we haven't seen ever in the history of the industry." Expects "record numbers of transformational medicines" over the next 5–10 years. [Insightful Investor](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiB3wOybZr7uTJBLWtNSOkxDzlEa96YLa1uuVTpwHilUIODPV4T-2BO8piI-2BsK-2ByAwjY4CGwvBb7PgGpErlbegtpTsZl-2BTyqt242-2BNRDiWHMX2g-3D-3D2AjE_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V6FJdVR2DbwIPwiMqAAZ7l5-2FHKnTdKU5XpUrgzL9-2FtsGIoUr-2FclbEn0kuC-2FHekrz9ZOWHRZa4YCzPdk0HQqBxfJH9BI55z-2FS308LV-2FqPPpGFRtxV5faUhiizgivxfbKwxw-3D-3D) **Steve Eisman.** Offered a contrarian take on healthcare as a defensive play: healthcare was "down 5% in Q1 2026," underperforming the S&P 500 (down 4%), with "wrenching problems in every one of its businesses" in health insurance. Characterized UNH's 10% rally as "mostly short covering by hedge funds." [The Real Eisman Playbook](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjc5aPP6aH0J2G9y-2BwxdUivHOac4HNctw3sRmMUBrkwC7oWRtR3eqJIJtRaSmNxmBcb27YHFM9yLZivb7-2BsJAeHvsrH8LaQDOEZPIwMSheupA-3D-3DQavT_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V9BEd76sI0GIuROCZwrtsn16O2zmNdXIM8FGEdbbUHSePR0v9FMyEXnBtbl7vLn3qoGEe91Hp4e0DBl8z8SyBRS0bWYNf5TfRXJJL1f23gLNjmZMjgzI1TtVnv6Z0oNh7w-3D-3D) **Josh Schimmer, Biotech Hangout.** Framed the sector's maturation thesis: "The biotech sector continues to mature and continues to look quite investable for those attracted to things like cash flow... companies transitioning to profitability and bottom-line growth and really meaningful cash flows." Made a key structural point that mid-tier biotech M&A "keeps these companies in the XBI... maintains strong cash flows within the XBI instead of transferring them to pharma." [Biotech Hangout](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOj8LUgqyKPHfA5-2By75OCa71nfCnkMjc3W2I9-2ByENTnY8dVyVWvV4y-2Bx98Y2HMidFb0ToBFj5s-2BerV3ebqnNv7AW79CiCQwIHsOXn-2F-2Bfg26xZw-3D-3D9tRo_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V-2FR6SrRw5MHD4pX1IAsLD4rbMDgBvq7fXdQ-2BOpgScy8hLOsXEsWA2G6FDh8EJ2ByS1fxZmBNxZ4etBwTvizDbSm2Ocv3vTv2tUOHDspj81A2Blkcu-2FzhVAKYr5odztWMQg-3D-3D) **Dave Knapp, On The Pen.** Raised a contrarian safety flag on Foundayo's liver monitoring requirement: "If liver safety signals emerge for orforglipron at scale, it doesn't stay contained to that one drug... They're going to say that's a GLP-1 problem." Also criticized Wegovy HD's dosing design (3x jump from 2.4mg to 7.2mg with no flexible titration) as "literally crazy." [On The Pen](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOheYuA4-2FEGhQw4KFzbCVPwjksu6n8NNuaG01HZ4oJFHqBk6wbQFXFarFbiJeuO7gjrwEAxrsJLCUIKCG5h9MBDMpruxP1NntALdtkLEVKy5dQ-3D-3DWPAl_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31VxJ4-2F-2BFKZo91aFPsFJfwYXV5sw3xYqZy9SE9yujggzu-2B6BpbkfgUDhds5-2BISK-2BxaDHdlat0bqScFccFzkSb-2BeEGD5Dz9mly-2FlBIoY0QLnKlaqS3kH-2BaO2pJXe5SaYLPECQ-3D-3D) **Sam Fazeli, Bloomberg Intelligence.** Characterized the 100% pharma tariff as "much more about form over substance" and noted the market "hardly blinked." On the GLP-1 competition, suggested oral formulations may serve as "maintenance therapy" after initial injectable weight loss. [Bloomberg Intelligence](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhTTvjZqtdAHZPa3E1IEg3ZexpOnQ3HA75hrjBcyc4N1mv9QCK8FQoYw2TZY5ab3GZMoM2BcnVy-2BlkMh-2FKRIL-2B9C3dzEW7w065S4pa4GUJpPw-3D-3DjUWr_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V4B4VhpUcwsQcOQhqXJRLWmRUSbqq6pfvgzkDqYbMOWo8ZkvuDhGmvCckXd7u17gC-2FDHimOnAcoZ4kxv-2Fk8NtrZ-2BDHpq9fI-2BjbF44IAlMTT-2BnoSvXUDvOJbpruLXe4PsjQ-3D-3D) / [Biotech Hangout](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOj8LUgqyKPHfA5-2By75OCa71nfCnkMjc3W2I9-2ByENTnY8dVyVWvV4y-2Bx98Y2HMidFb0ToBFj5s-2BerV3ebqnNv7AW79CiCQwIHsOXn-2F-2Bfg26xZw-3D-3DTzNU_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31Vy1-2BeYFmJIfGx9RKAoQXlAr7nt12zliozZ2J3fp7MWwMypPxVZOwuQtaMLwsJhW3iVGQ3jphSTvvdmQBWHKsusoEX5sgZV-2Fs5Pv78WtMmJN2GOgrISNQ6-2FQAqNYicLA8sw-3D-3D) **Laura Nelson Carney, Capital Group.** Offered a balanced AI-in-pharma view: "We're probably overestimating the very short-term impacts, but profoundly underestimating the long-term impact." Flagged that Chinese biotech now accounts for "48% of pharma assets licensed by Big Pharma (by deal value)," and highlighted RNA interference (RNAi) as a key emerging science with "50+ Chinese companies" working on next-gen applications. [Capital Ideas](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjc8kmw0JDFHUpCddxu1V9An14Lu-2FVM-2FpGb6ClE-2BJHum27D2J08B1ObVrlsTXdFw-2FtdY8WUwywtYBIyBzKqS2q3j533vo2dQ5F72BKV0PTRCw-3D-3D5CN9_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V7WrGwL7Oex1kdmOT3gEK-2Fn8uzBnO93rc5qLB01fa3AhJLCib5EUz-2BP00hqguWaHzDDR1JUOLb6kvZF4I3FLK6zC-2BAGeZWDmRTMVXc5sc2Y7WXhtYivn5ceVqa-2BqYfkMaQ-3D-3D) **Travis Hoyum, Chit Chat Stocks.** Made the contrarian case against legacy healthcare infrastructure: "I would be very worried about owning any of the existing infrastructure in healthcare. So that goes from insurance companies to the hospitals... the incentive structure that's in place today is so backwards." Pitched HIMS as "the Netflix of healthcare." [Chit Chat Stocks](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOihouZChik-2FmXA2GUPMxE7S5MAojkeJKp1J0hk7dr3Try5c7Q89wk-2FlI3xmu70JPEg-2BcBfAnJr27zfSPsfjU-2F8P0yMZqQApVNZa20UGqFDUfA-3D-3DpT6t_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31Vw2Rz2-2BWxNdxrqYTgvRdgKnF7OYzMoAKwUZNbBqprA5qMBW8SzvlOTeK0XEgwP9altC6jy-2Ft-2BoM0TgfvUhuP-2BdERCg-2BxJbGsEpG0WCwR1DALhtK-2B85eBrmifHk-2BiKjcZrQ-3D-3D) --- ```request-access variant: inline heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` ## 3. The Key Debates ### Debate 1: GLP-1 Oral Efficacy vs. Convenience, Who Wins? **Convenience camp (Foundayo/Lilly):** Foundayo can be taken with food and other pills at any time, unlike oral semaglutide, which requires an empty stomach, 4oz water or less, and a 30-minute fasting wait. William Blair analysts stated Foundayo will "blunt the uptake of oral Wegovy." Cash-pay pricing starts at $149/month. [Diabetes Dialogue](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOie1E-2BSjDS0W1ChktOp61g4VFZC4kFtVqeOZTL-2BafhHZqS27owz5RL1um5Aa61GEC2VDpVGhCdOWazq9cslsG3Tn5SAMNJxoHdP452ObJWX2Q-3D-3D43Rb_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V-2F9Mcqtc-2FDMbY8K1uOA3FF-2BPtVRJnhSuM6JbL3t2AFe8ovhTCpiPGvmvEP8SY43GtHTCi-2BCXRys1wzuFRGcINZSF7YcisiDxWquc5axOc6blKe0bWqx3FlDTqPSjKiGUPw-3D-3D) / [BioSpace](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhzOs0FIhw2yH3NUAiAy5Yb-2BQhLr172QlwxFrhRMd0fHs1VxNfsBO6wwup6yQP3YKkfMReTiRgOWX9Z4GxOzbF0shlWYN-2BUYtQKVpS0YlAIOg-3D-3DbNNE_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31Vz2-2BK5W7L685eMPZ9tAWsMUPzjRzd0vPqgEa3y-2FCfVWemxvFs-2FiRmVT1K7fs7DfeX26fdCdNp5N3sYxN-2FwNepZL9X-2B5JyAFwN2lDnGq5bxHn4euQmLAKPogEXzKh0p1Q-2Bg-3D-3D) **Efficacy camp (Oral Wegovy/Novo):** Oral Wegovy achieved ~16% weight loss vs. Foundayo's ~11.2% at the highest approved dose. Injectable Wegovy HD (7.2mg) produced 18.7% placebo-adjusted weight loss with 47% of patients losing 20%+ body weight, "results we usually only see with weight loss surgery." [BioSpace](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhzOs0FIhw2yH3NUAiAy5Yb-2BQhLr172QlwxFrhRMd0fHs1VxNfsBO6wwup6yQP3YKkfMReTiRgOWX9Z4GxOzbF0shlWYN-2BUYtQKVpS0YlAIOg-3D-3DhW2y_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V0NwwluyCtEOQkdko-2BlLmAlbC-2B-2B78jpdmZArBPSv14yHNQewb9hq-2BLx-2FoQLNYVRbEI4PIGgmuWjz5hlmDs9l5cyNz1y0ofbHVcHZUijkZxAzdhCZP35HvM6Kv1rPohXrlg-3D-3D) / [Back on Track](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOh34wbyiLvERObxVAsaVC-2FHXndgy4PmPJxtrxyqVdtxKh55JHoN3pshqUHjZxNgQfHExOQ-2FUVgd1ogqjs3v5KdPA7LARvBtAmfK3IcOVGCHxA-3D-3DvRcO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V9K7qjl2B3rRniTCNCmdCgHXfokgr7TTjN-2FZ1mXEk43SKg-2BrjgCUZZW2Ccg4eKxFsZprWCXXN6XHEO-2FKGS83ciFmgC3NgLcl1Uw8VJSIybJi-2Bj6jvRqcnlWi3IL9hpF3hA-3D-3D) **The safety wildcard:** The FDA imposed specific post-marketing liver injury surveillance on Foundayo. Phase 2 trials showed elevated ALT/AST in a small cohort, and the highest dose was reduced from 45mg to 17.2mg. Meanwhile, Novo faces an FDA warning letter citing "systemic failures" in adverse event reporting for semaglutide, including unreported patient deaths. [On The Pen](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOheYuA4-2FEGhQw4KFzbCVPwjksu6n8NNuaG01HZ4oJFHqBk6wbQFXFarFbiJeuO7gjrwEAxrsJLCUIKCG5h9MBDMpruxP1NntALdtkLEVKy5dQ-3D-3DRxHJ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31Vw83F7md8LkHdLpTKcEIm1uJbmXDPOx82X4Y3g2IItIJTJJyWeqRK9pBhbDj-2FCmOS3mDPKVtxX-2FNxg3wVOzU3diwjxskrzynmf6wuEYKFKMx9HDG7fzNfJMwUZb-2BrIwtoA-3D-3D) / [Weight and Healthcare](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhUFU2HW2zH7b108iRNrcFnR-2Fvd2gHfFWjFOklLDndwF-2Bgf8bEucDBfpSl3SW0gfDP336tvnWZL3p9RuCqdj87V6ZRMKrryU15zS78bwcBwhw-3D-3DKDQ__7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V5K3c9glqXg6vmZsAPsZJhs4Gz8-2FrctqJyecr-2F8XldU9aRMLVaVu3BEDMlXWHiWVRWDxHtbWcG-2B9HMTVxh7Sk7cXIQmCYzjD-2FFvId8P9vgk0F9O3AzZEHMHf9C7Tt7bLFA-3D-3D) ### Debate 2: Eli Lilly Valuation, Growth Compounder or Priced for Perfection? **Bulls:** Bill Gunderson has LLY as a top 2 pick for the year, with an EPS estimate of $42/share, revenue growth +40% YoY, FCF growth +80% YoY. Amazon same-day delivery of Foundayo at $149/month is "transformative." Retatrutide ("GLP-3") pipeline catalyst "could indeed be a trillion dollar drug." [Best Stocks Now](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhAEG6BvlMvVVv3XpQUiPTpddkwUP-2Bc1GRdWiDa8RFtfuLzbzS-2Bk0SrIJ-2F78fr9z2mX1j5RkkLhRfpi7uphUTB8r5XHn1KPKQ2UEvypZ6v54g-3D-3DXcmD_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V95Idb292M6BGWgmeObVYrGaLiZLse92cD9JzeRzH5e9pgMR5lthYl9ph2pUe1yPIICGnHdWC-2B5-2BkDtPC1bZhFjLqKi-2FRZCUToBbAXb-2Ba0VCPCDUBU2kYbD999G-2FvMSvRg-3D-3D) / [Chit Chat Stocks](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOihouZChik-2FmXA2GUPMxE7S5MAojkeJKp1J0hk7dr3Try5c7Q89wk-2FlI3xmu70JPEg-2BcBfAnJr27zfSPsfjU-2F8P0yMZqQApVNZa20UGqFDUfA-3D-3Dt4wf_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V0dxqV6de5Gau9EkQIRWvQpz2SBGxBhCfEp52uK8b3DmjQ6SABytHZgT-2BPT-2B4rOCog1O7apm5Cc16G0JqPZaz1fkkU2NPqcgWBf-2BoMNJEMEL40-2B5AMJ3O17tJkmnRXA1hg-3D-3D) **Bears:** Jason Wallace argues LLY trades at ~50x FCF, more expensive than NVIDIA at 40x, with "barriers to entry lower than that of semiconductors." He warned: "I don't think these drugs are the giant cash cow that they have been." Patent vulnerability is real: "a blockbuster drug can go to zero overnight." [Telltales](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiPoBbvuJeEZIhq1mC2FSOWW9wDCgR5CU3-2F1NbIVp3nTntEnM5BDL4RdGkGSx4mj-2FcxMiTI00PX0i5EOO5dTCgDyn8HUs10VYGWvmvHko8aQw-3D-3DAsN-_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V5TEuiIONGby0Y33iGNh7PKanx8c1BYzfEGXlqcpmSlzQ-2FMOzA5RYThwb4Rv1EyhOz8AqvF01m84tx7qFzU4jhEkQtHyY-2B-2BWuXkEq-2F-2F8koNkekyiWblOKNE4pZ64-2Bymc2g-3D-3D) / [Telltales](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOj2meFHxLyxbKf0-2BtTmUClG-2FBKKPqbZc05mZe6Dx0y5Qg9pRcM20eqEqJAW9Wg85OtFz-2FFL-2FYksZjl2XgqrchOK6u-2F5RqyhhxXrmey9KLMfww-3D-3DjdV1_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31Vwi6G0nRqe-2FBRBmOb1FKw-2FiRqkSYMBPkI-2By-2Fqs-2FM6Dp9XhXjYhXYwTBJUaERyIAJJ-2BoiT-2FUY-2BFjvPHjrlvCVvarJ-2BPt7YEINDVa1dKy6gxg0OkO14YTY5stl2uRdL6u-2FZw-3D-3D) ### Debate 3: Medicare Advantage, Real Relief or Industry Capitulation? **Bullish read:** Goldman Sachs expects UNH and CVS to anchor Q1 earnings commentary on "multi-year margin expansion" following the finalized 2.48% rate increase ($13B more than 2026). Jim Cramer is bullish on the managed care rally. [Squawk on the Street](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgY-2Fd6pnXe7pNqNNqLjTy18Cpj06rtEccba1hWDq-2B5Y7npQTfAKqa78FQbZKEoIMoIuhYVfcdv-2BFC4YJHvILm-2FgDeCLggkccXOYtiqsyoBu8w-3D-3DUp1r_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V8MQw43H0UvfQkPGtPc3DPeT0PB235tb2sVGGOHm-2BIOXa4iqKLs-2BX9IcTG-2FAf5zRJ5DZcA9dInkIRrJRN2P5VqgcmTkpxEWek6fVZRITAtX8I0kRiGbyH8p2FCnDCO-2BP9w-3D-3D) **Skeptical read:** David Meyers (Brown University) argues MA plans are "overpaid 5–20% relative to traditional Medicare" per MedPAC, and the V28 model delay represents "capitulation to industry pressure." Steve Eisman notes UNH was "down 18% in Q1 2026" and the rate isn't "great" vs. the 5% investors originally wanted. Chad Mulvaney warns rate improvements are "unlikely to result in reduced tensions between plans and providers over prior authorizations, denials, downcodings." [A Health Podyssey](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg-2F-2B5lPXXPzTD8r3kpi8f7hVIr-2FnhPcW7Gd3a-2F6oqlMO5CvBMIzJS4SwIRHLaxlg-2FSeZt3863iezB4nFh14oYIuZHaB-2Fno3je17h8XC-2FQg16Q-3D-3Dey3s_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31Vx6ehoD572eToYyzsG4E7pr2eAR4-2BmllLD-2FP2GuOmcB-2Ft850Hly-2FfFDuO7FFGvUSnnZ-2FvIomU-2B673xYhhufBzNKDsl3BAIcj0te70S8jqAxXrr5emes0WHCGf5ES0dCWUA-3D-3D) / [The Real Eisman Playbook](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjc5aPP6aH0J2G9y-2BwxdUivHOac4HNctw3sRmMUBrkwC7oWRtR3eqJIJtRaSmNxmBcb27YHFM9yLZivb7-2BsJAeHvsrH8LaQDOEZPIwMSheupA-3D-3DXNR1_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31VxTJ-2BH4-2BHyTk8EsxpD1cB8LxzD1dvmNPIl1I2DfscD-2FhLoBfbn4n-2FNApECv6YymyWutMDwfhL2-2FXv7phFsIsucK-2F1JPayDR-2BLr6zJHLHi1N7E9YNQqbC8y2rQjboam6kWw-3D-3D) / [Achieving Health](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgW-2Bs206ohRco2P1NQ3y8mrKFZDPHD9SmVjH-2BDwGwvLPleVDIr2LDMZA7-2BOsjtc8o3lRMMO3IZOki-2FqRl-2BVlSbO8sq0F2ecwDVfK59KwOfHww-3D-3DCYtd_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V-2BPTVoo2qfzuqKGu1xIMmXHncqNf55s9mubQn5xAz1cMXQXzfy0scwF745qvDtgLogoq9RUqUO56VDmi3VxXXwFJ8YV2-2FKTyQ0bYQLYqbUx1YFQLduuF-2BmJueXRFByTIFQ-3D-3D) ### Debate 4: Healthcare M&A, Sustainable Trend or Peak Cycle? **Bullish:** Paul Bananos (BioCentury) tallied 7 deals totaling >$28B upfront in just three weeks. BMO Capital Markets predicts 2026 could reach $172B in total deal value, a record. Mid-tier biotechs emerging as acquirers is a structural positive for XBI. [BioCentury](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgUop0i5ya8KJoMZaGAhtcjoZA6GPfkrWKf3rg82pFCW3aSwTxjBI8n6mxZ79pJbvm2QsIMl3q4LDfKLR3YROpmGX9PEc3gjA3-2FPj19TV-2BKTQ-3D-3DxwKd_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V-2FrsCwfZy538vOnzYsy1WmTj4pZK0yy0KVK26SJKrTsOsdepHuofTnsSegyLa-2BXiHPsWT73F1trHzXCkmrDkSPcrvJlAV2xf-2BpL1q1kmcDsbBvigOkNG-2FNFvJyzDV7Jpdg-3D-3D) / [BioSpace](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhzOs0FIhw2yH3NUAiAy5Yb-2BQhLr172QlwxFrhRMd0fHs1VxNfsBO6wwup6yQP3YKkfMReTiRgOWX9Z4GxOzbF0shlWYN-2BUYtQKVpS0YlAIOg-3D-3DdKX0_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V-2FhSy8m7WmYn2vEP0FEro8Gf4RhDTO239OCRbo6ScyOpN8J1o6PmvcQcouxgBuczsjusy1jF4zgNa1Uc0bLTN4FF0Guvdt7eydtxb1YmZvqTd8ANavvzR7Bcs4a-2FW77FQA-3D-3D) **Cautious:** Sellers accepting lower premiums ("Calaeno sold for ~$3B. At one point, it was valued north of $4B"). Merck's Terns deal saw efficacy concerns emerge post-signing (degraded from 64% MMR) and a competing bidder dropped out. VC fundraising was "the lowest amount of new funds in a decade" per The Readout Loud. [Biotech Hangout](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOj8LUgqyKPHfA5-2By75OCa71nfCnkMjc3W2I9-2ByENTnY8dVyVWvV4y-2Bx98Y2HMidFb0ToBFj5s-2BerV3ebqnNv7AW79CiCQwIHsOXn-2F-2Bfg26xZw-3D-3D6pVJ_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V8FU0q-2FtKQIkb373zsYlKm-2FLvuG-2BVNtCOjpGMRMvtMdvNWI6j2j6g3WaZNQWE7mjK2e330cHoP5kUBHkhcd7gW5llqMLbdo1CWncyYkzo-2BCGnwayjUOXik9MrHjDp9ZAAQ-3D-3D) / [The Readout Loud](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOia8DH7mFByxAR-2Bw4zVpA3sTsCGiN9rofl9a5y0ddhAfnFmQPMBNvRHd7hFblxJQYnC96Fz1bmD5yDDn9ZHXObCoYLJbU6KlqITzWElhjH2FA-3D-3DkcmT_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31VygnZBgZtlYnvam-2BfsGqk4EU648uOxuKa-2Fj9VWAs988408ZaR2WjXw2uX-2FOO0uA0dUwLn7dL0Fsts5gB-2FRS70rAXq8pepg5mtaGC5ltfUpwj9tdoP7vDvoPctKVk9GAYSw-3D-3D) ### Debate 5: Pharma Tariffs, Material Threat or Political Theater? **"Form over substance" camp:** Sam Fazeli noted the market "hardly blinked." Jason Wallace agreed: "Overall, a 100% tariff on the active ingredient is not that big of a deal for a mature pharma company." All 16 big pharma companies with MFN agreements are exempt, plus generics, biosimilars, orphan drugs, and cell/gene therapies. [Biotech Hangout](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOj8LUgqyKPHfA5-2By75OCa71nfCnkMjc3W2I9-2ByENTnY8dVyVWvV4y-2Bx98Y2HMidFb0ToBFj5s-2BerV3ebqnNv7AW79CiCQwIHsOXn-2F-2Bfg26xZw-3D-3DJ3zM_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31VyL-2FYMtxgBmyQiO3feOxu0e1-2FsbXoSjldf2rqAeHNWjnN3I04R3RRbTpgcjOkAPRNffZUfnAlJq-2FgN0ej3u8Exg-2B-2BvwBRWg-2F93vmi2cXFytyYQ-2Fclx2hh5vUMOncuzAenw-3D-3D) / [Telltales](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiPoBbvuJeEZIhq1mC2FSOWW9wDCgR5CU3-2F1NbIVp3nTntEnM5BDL4RdGkGSx4mj-2FcxMiTI00PX0i5EOO5dTCgDyn8HUs10VYGWvmvHko8aQw-3D-3DUy14_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V4FreQo6HDJC2zWrktrtHhIaCHkjXXDQwG6RUFPiUEvyS64BGBIuPei-2Bfnd8vizR5-2B-2BrfovejxnIIFHpXaS-2BPlbRzlMLCGZ1wWDbdVx-2FuLCQsLID6lidZrn-2FQpjJ382qRg-3D-3D) **Supply chain risk camp:** Brian Doty warns 83% of the top 100 prescribed generic drugs have no domestic API source, and China supplies a quarter or more of U.S. drug active ingredients. The Strait of Hormuz standoff has created a "petroleum-to-pill" bottleneck threatening generic supply. [Off Script](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgxzH1dESpuj7aji3gj-2FWPUWqss74w-2BKbq4gCPO14YoVYL7Z4m0Xsw57MmDO-2B1lB-2FVjro6Xqof9cqyrxZZlaFJOJ4HHxUoYQJ55x0FT0-2FxY6A-3D-3DmoHR_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V1-2BMDIAvbkruGnBNAd-2F-2F14dRSmmXmaEL6QsJ8duJOIOUhWEwDu5zQncKFj5VW7RiBAdBxnQFCUQ6obJK9IzIsjYY1glC-2FKSu-2F0P0o0zDjRDqrNdgqlV1tU41BsOdRlJlAQ-3D-3D) / [Web sources](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NpdglUFCUv6LFq-2BUCLyALtxdH4V5kiyjIh00eBl9rtF-2FNn3oS8HA1n07OoXknj-2FLPA-3D-3Da_60_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31VwQZfDwZwSoz-2B1ARST1F9QIWkqjn8ZegRZfgVZPo4eEqju1-2Fb8WMP70dKS-2FiJplSq4D0wctFwVd-2FUZSTsaeWE9l4uYZi2avsIrE6f053mm-2Bn4CEzM7hrMSk-2BewRQxRpA7g-3D-3D) --- ## 4. Hot Topics Under Debate **Revolution Medicines pancreatic cancer breakthrough.** Clinical data showed a doubling of survival in advanced pancreatic cancer for its RAS inhibitor Diracxon-Rasib. FDA granted a Commissioner's Priority Review Voucher (1–2 month potential review). Shares rose ~40%. BioSpace called it "truly the most exciting clinical trial results of the entire year." [BioSpace](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjrcUyB3nrQM9J82mBTI5-2BHcMpy8h70TQnNPVFU-2BHw1FAeB1egAPNsJR7eYPgeV7u6-2FxrTQWButnAnJgSkadxHDkJbsSPnakKiUEi-2Bfxz5YUw-3D-3Dvof8_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31VwZy6JmVQYfUHAbHY-2B63JBF-2BG7LlBRXV0QCjmCgw68HIHW8S5vcH7DSZZQgKnyHiwBpI5oYe8mzSy1HtbZ-2FIAuq2HifR4iOqLpl9iM-2FIYRyLY9uC7mzvFMVTFc3qDArchA-3D-3D) **Foundayo ACHIEVE-4 cardiovascular data.** Eli Lilly reported the Phase 3 ACHIEVE-4 trial showed Foundayo had a 16% lower risk of MACE vs. insulin glargine (meeting non-inferiority) and a 57% lower risk of all-cause death. Critically, "there was no hepatic safety signal," directly addressing the liver monitoring concern. Lilly will submit for Type 2 diabetes under the Commissioner's National Priority Review Voucher by end of Q2. **J&J's "beat and raise" Q1 and Icotyde excitement.** Q1 revenue $24.06B vs. $23.61B consensus; EPS $2.70 vs. $2.68 consensus. Raised FY26 guidance to $11.45–$11.65 EPS and $100.3B–$101.3B revenue. Management called Icotyde (plaque psoriasis, approved March 2026) potentially "one of the company's largest products ever." Analyst upgrades poured in: Morgan Stanley to $283, RBC to $265, Barclays to $255, Stifel to $250. **Anthropic acquires Coefficient Bio for $400M.** A 10-person stealth AI biotech less than one year old. The CEO of Novartis is joining Anthropic's board. Health:Further called AI drug discovery "one of the most promising early uses of AI in healthcare." [Health:Further](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjew3rLELzsFTSEQ0YAdWrLOAF13x-2Bo-2B1N-2BDdS9hAzolPeBaSVInOtjVYvjae42iko5gWqqu6XqXDULtAk6kCY8GAJZkXsrLAG4rp69SHUrQw-3D-3DD2KH_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31VzPkhLWw1A540Q1yBF-2BT2y9XUmM7S7CcK7k-2B415VTtKPK6V6aWqVxsEQeRYVOkQhup0-2FvGkVXYLy1uWQqGXZz6p073ro8GG4ElRbzvhPTXV8y3NjLpeOBk85dXyQyfCdrw-3D-3D) / [Telltales](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOj2meFHxLyxbKf0-2BtTmUClG-2FBKKPqbZc05mZe6Dx0y5Qg9pRcM20eqEqJAW9Wg85OtFz-2FFL-2FYksZjl2XgqrchOK6u-2F5RqyhhxXrmey9KLMfww-3D-3D6JtT_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31Vx2E-2FwHmcRPQlVe4mAgc-2FJEqPiy9BZKRti5VXhwd5Mr1ghknwOVPHGVKwfRXb2USwaDCPwGVuK3OF4elGhKLaNZUTh-2FwgIIq-2FrNZcG2bCYXTszv9D5nAiTr094-2F4GH7plg-3D-3D) **Lilly's LillyPod AI supercomputer.** ~1,000 NVIDIA Blackwell Ultra GPUs delivering >9,000 petaflops, "the most powerful AI factory wholly owned by a pharmaceutical company." Lilly committed up to $1B over 5 years in an AI co-innovation lab with NVIDIA, aiming to "cut the traditional 10-year drug development timeline about in half." [ChatGPT Podcast](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjdTHuyq15nimMuBbSxM1CClPThmYfA2arQPtcHoh0QJWSy4dWcgaoNcjIDcryFQblx-2B7EmAbPsQUDFRyMggHsNG9qyglR7fwsUMGMkKGkOvQ-3D-3D4Bl5_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V5vbExD6KdYVcA1aXcH6sSHf1E6l7Pe2e50UZob1QqZ9zsInsoRkhgKC53gV-2BbY4y-2FwR8w1AHG6dW-2FdEiz0kZQlU4QvRIjYB8WnogCQ12Op0hhjn9GlMxwaNd2QW5oXAfA-3D-3D) **IRA impact on oncology pipeline.** Duane Schulthess (Vital Transformation) reported a 37% drop in oncology small molecule secondary studies and a 27% drop in lead Phase 2B assets since IRA implementation. He warned of VC flight: "We're seeing VCs leave the marketplace or move to China because they're getting a better ROI." [Vital Health Podcast](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhdA75VzyhmbdIlc-2Bt8RXEod-2Bbjegb3cSv5PcDLJ1wPjEC8mrE-2F-2B4hASReXsN8t1aebtTS3CM7GQ4VItKQ6zVtaUsL6TyUwAR9LjRCzkezeew-3D-3D_YLc_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V2w-2FHOtZn-2FVwsHfGGPIrDU5lPTc-2Bj7XKxCYUtINccgUeyROqMV5UYfwr4PkrpldyQCmu3WwJayY7PdMEkNi2xixCBBiQhyCT3s-2FA-2Bp5eHCGX2I5ngVKg8abgnhurWZ2jYw-3D-3D) **ACA enrollment cracks.** Around 14% of ACA enrollees failed to pay their first bill for January coverage, vs. a normal mid-single-digit drop-off. Bronze plans with $7,000+ deductibles now account for 40% of selections. ACA plans denied 19% of in-network claims in 2024, the highest since marketplace launch. [WSJ via thefly] / [Achieving Health](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgW-2Bs206ohRco2P1NQ3y8mrKFZDPHD9SmVjH-2BDwGwvLPleVDIr2LDMZA7-2BOsjtc8o3lRMMO3IZOki-2FqRl-2BVlSbO8sq0F2ecwDVfK59KwOfHww-3D-3D69k3_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V7U7dKDBIznLVjTnQBZoX4VK0IztazClMqgzvtRfhRMd6UiNW2ADiWH-2BQtuUAACtEZxwhXjeJiGLH8vgh4UPHMY0McCNI8y5vZUpKyQJK3Mi5GBUBMPSevgAIo9DV9f-2Bqg-3D-3D) **Trump names new CDC Director.** Dr. Erica Schwartz (former Deputy Surgeon General) nominated as CDC Director, with Sean Slovenski as Deputy Director/COO. Implications for pharma/biotech regulation remain unclear. --- ```request-access variant: inline heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` ## 5. Emerging Themes to Watch **The employer-direct GLP-1 distribution model.** Jay Bregman (Andal CEO) described a platform launched with Eli Lilly offering Zepbound multi-dose QuickPen at ~$515 total cost, bypassing PBMs with no prior authorizations. Only 1.2–2.5% of eligible employees currently access GLP-1s under traditional plans. A study in *Obesity* found nearly 20% of employees would look for another job if their employer discontinued GLP-1 coverage. [GLP-1 Studio](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOh-2BkFs6T6wPnp2nYpqt01a4Q-2FXi-2BicPCGc9ONeKViwklrSN-2FEGlxbeQDhd0b1VnX0owPghVeecl4M8trh-2BKMGaqeN5zwO4Rkd0Rcf7XcYJ8Pw-3D-3DHemw_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V48kNOy08mpeDSfQoQkZD3ogXqdQD6xBJbx8C3oXNg2d-2F87kv5dqe0UnkYF-2BALn4Ndd2ziMfo7wOkl1PKJ2xq8eCfExHmDyot8-2FkX5kXCchO1vM1WTIj0k4waXGFrcNVfg-3D-3D) **Mid-tier biotech as acquirers.** Oliver Barnes (Financial Times) highlighted: "Now there's more mid-sized drug makers transacting. That's going to be good for the sector... more buyers, more bidders." This keeps cash flows within XBI rather than transferring to large pharma, a structural positive for the biotech ETF. [Biotech Hangout](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOj8LUgqyKPHfA5-2By75OCa71nfCnkMjc3W2I9-2ByENTnY8dVyVWvV4y-2Bx98Y2HMidFb0ToBFj5s-2BerV3ebqnNv7AW79CiCQwIHsOXn-2F-2Bfg26xZw-3D-3Dvau9_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V6DKIYFAtCXHy3Q-2B9uTsdFHnYPlHAxrgQkuJDMuuXjC4-2FJdB0fNlwfxXheqdRRorpQwA-2FsMVaPbQ6sQkYPiRcGSnBI16HcGJOPFKCTBezEGE3QCzMC-2BgilSgKsRANJdbDw-3D-3D) **Chinese biotech licensing dominance.** Chinese biotech now accounts for 48% of pharma assets licensed by Big Pharma (by deal value), creating a valuation pressure dynamic for U.S. small-cap biotech if investors perceive innovation parity at lower cost. [Capital Ideas](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjc8kmw0JDFHUpCddxu1V9An14Lu-2FVM-2FpGb6ClE-2BJHum27D2J08B1ObVrlsTXdFw-2FtdY8WUwywtYBIyBzKqS2q3j533vo2dQ5F72BKV0PTRCw-3D-3DNV5O_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V3h-2FpF6aB91Ktuoex9KAIsjB-2B2OGk11df1lRf53FsjfaJ18VokP9g99izb42bGY3sthpJx-2Ff0kv5-2FJRmB6c3Dh8rH8sLD2jwW4QNI-2FT7aAWi1nA-2F8s0-2FRpfGgts0CuVwSA-3D-3D) **GLP-1 price collapse and accessibility explosion.** GLP-1 pricing has collapsed from ~$2,000/month to ~$150/month in three years. Market penetration doubled from 3% to 6% of eligible U.S. obesity patients between 2024–2025, with TAM projected to reach $190B by 2035. Robert Pearl (former Kaiser Permanente CEO) cited Yale research showing GLP-1 production cost is $5/month vs. $400/month retail, an 80x markup. [Chit Chat Stocks](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOihouZChik-2FmXA2GUPMxE7S5MAojkeJKp1J0hk7dr3Try5c7Q89wk-2FlI3xmu70JPEg-2BcBfAnJr27zfSPsfjU-2F8P0yMZqQApVNZa20UGqFDUfA-3D-3D7247_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31VyWcTT4JF7kVXdqhBkLL-2FTHr8nKUDdgq-2BfsF-2Fsw8tdnsc37bsV04uHoFeVYUnZmFItCF1Zj-2B7RRd5vnMDzgSzavdGv5-2Bt5tVchkSvXgESCGtgHos-2BP8OuBuBxW7B-2BvipJw-3D-3D) / [Keen On America](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhKRbkoa-2FqhPf2mwA5-2FCZRt9oJaGTKKd-2BFP0w47-2F0vfoMQJLIY2RC9DFmylrrh2WnP3Omw9XS2Mp2YOfk8Nk4g4LboUWBAMuJN7q8h7wpa8GA-3D-3DwlaO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31VyDELesb8I5ll-2BHGUwuLhHhbidT8i-2BQ2sAMHLH8-2FM0nZyH9ftVUHLClAbFikbneEQaFI4MvHM17H0k4KQMu8mQOnQh5mEyhkV61-2B8mMMPeRc-2BQ7H35LB6DnsWw0KUq80PA-3D-3D) **European pharma launch delays over MFN pricing.** Some pharma companies are rethinking European launch strategies, considering delays or non-launches to avoid setting reference prices for U.S. MFN agreements. BioSpace editor Annalee Armstrong called this "a really dark moment" where "European patients would be actually denied new medicines just so that Americans can be charged more." [BioSpace](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhzOs0FIhw2yH3NUAiAy5Yb-2BQhLr172QlwxFrhRMd0fHs1VxNfsBO6wwup6yQP3YKkfMReTiRgOWX9Z4GxOzbF0shlWYN-2BUYtQKVpS0YlAIOg-3D-3D0Xcc_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31VxQtKBZJ6BS7QCipOw8g6iz2RRb-2B-2FIOXrDFbwslT2Oxqw2PqllVupgx7N-2BfJfn51TAnkNSsi6kguN-2F9UyS95o7mig77t7ngCQeNHb3Ck-2BNjVRX6Z6Wm7FDY-2FqwrHCQe0bg-3D-3D) **The biotech IPO window reopens.** Kyliera (obesity assets from Chinese biotech) planning a $533M IPO. Early declarations from Seaport, Avalyn, Hemab. Eikon Therapeutics raised $381M, Generate Biomedicines $400M. Blackstone Life Sciences closed its second fund at $6.3B. [BioSpace](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjrcUyB3nrQM9J82mBTI5-2BHcMpy8h70TQnNPVFU-2BHw1FAeB1egAPNsJR7eYPgeV7u6-2FxrTQWButnAnJgSkadxHDkJbsSPnakKiUEi-2Bfxz5YUw-3D-3D4naa_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V8gc0hJPMXhmssNNW2aS8fpZowQ7ZcxC1JbJGEse-2BZ1B0-2Bi1oMdUxTy-2F6JLiqGqEW2czSdBlBPlJu09n1wlZVVEqpp1QDe2cjOMxwt8082bnakzZcen6z4PbWi0SwwRlvw-3D-3D) / [Web sources](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7Nh0hvJlNSFmBv24kBVDR3cRw9-2F9QKlMNQ8m9g8HJ7xOG7uzC565JYQO8RRWNuSSDghAkWOqyLxVzu2hlOnWhexSgT3oT-2FZuukvTC2WTlODBv1y_x_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V6rlID8-2Fcj2EiDGZAGnAbAt49IbEVnFgbhEg3k-2B94-2BqQSIywbF4lh8y4RQPnlMI6B8CGxUO8o1FfqgDZB-2Bl0TwpLTtCH-2BwcpUwU-2Bf5pU2hUamTkVHbtCYmq3yhI-2FIl4H3Q-3D-3D) **AI clinical scribes as healthcare AI proof of concept.** Dr. Robert Wachter (UCSF) identified AI scribes as the first validated large-scale AI deployment in healthcare, calling AI "the only viable solution" for managing exponential data from wearables and continuous monitoring. [Gist Healthcare](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgkqWebEqLP8O-2BBSdOHwlnOfYfPvWFRmRRensLSARfFeoeGMrvc68DBa0bD6OxYiIlWzJlVWRygBmX7FRCxQED3OGQFijYAh-2B9SyTTjhlX6jg-3D-3D82IU_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V4HSey3pjfFkhF8J-2Fso7HpsCRup6EInBsPRqS-2BOK-2BTOj1QULhuQa1-2F370trSHwp4FhTtFGSwr-2BTWE0y81f7X-2FwbbGyU9m9m7W7Gs6vM9C5ZMbMER-2FVDtdkw7E9UCJBplzA-3D-3D) --- ## 6. Stocks on the Radar | Ticker | Direction | Rationale | | --- | --- | --- | | **LLY** | Bullish (contested) | Foundayo pharmacy launch with Amazon delivery; ACHIEVE-4 CV safety/mortality data; LillyPod AI investment; Retatrutide pipeline. Bears cite 50x FCF, liver monitoring, and patent risk. | | **NVO** | Mixed | Wegovy HD launch at $399/month; oral Wegovy efficacy lead (16% vs. 11%). But FDA warning letter on adverse event reporting and tolerability concerns (25% couldn't tolerate full dose). | | **JNJ** | Bullish | Q1 beat and raise ($24.06B revenue, raised FY26 to $11.45–$11.65 EPS). Icotyde called potentially "one of the largest products ever." Multiple analyst upgrades. | | **UNH** | Mixed | 10% rally on MA rate finalization; Goldman sees multi-year margin expansion. But Eisman calls it short covering; rates below initial 5% hope; ACA enrollment cracks. | | **GILD** | Bullish | Three acquisitions totaling ~$13B upfront in 2026 (Arcellx, Auro, Tubulus). Aggressive oncology buildout. Morgan Stanley PT raised to $175, Citi to $165. | | **MRK** | Neutral | Terns acquisition ($6.7B) adds CML therapy but efficacy concerns emerged post-deal. UBS PT raised to $145. Exempt from tariffs via MFN. | | **ABBV** | Neutral | 340B lawsuit against HRSA is key catalyst; BMO flagged as having "space to make deals." Guggenheim PT raised to $249, Evercore PT slightly trimmed to $232. | | **PFE** | Neutral | CICC initiated Outperform at $33 PT. UBS and Morgan Stanley raised PTs modestly. Tariff exempt via MFN but ambiguity remains. | | **AMGN** | Neutral | Morgan Stanley PT raised to $326, UBS to $400. Flagged by BMO as having "space to make deals" in M&A. MariTide pipeline as GLP-1 competitor. | | **BMY** | Neutral | Limited stock-specific news this week. CDC leadership change potentially relevant. BMO flagged as having "space to make deals." | | **XBI** | Bullish | Up 8% YTD, 84% from 52-week low. Sector maturation thesis. But Chinese biotech licensing pressure and VC drought are headwinds. | | **RVMD** | Bullish | Pancreatic cancer data doubled survival; Commissioner's Priority Review Voucher; shares +40%. | | **HIMS** | Bullish (speculative) | Pitched as "Netflix of healthcare," $4.4B market cap, 2x sales, 30x earnings, 2.5M subscribers, 74% 5-year CAGR. Acquired Eucalyptus for $1.15B. | | **HUM** | Mixed (deep value) | Down 40%+ from highs; FY26 EPS guided ~$9 ($3 below Street). Some value models show 80% discount. Turnaround unlikely before 2028. | --- ```request-access variant: inline heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` ## 7. Upcoming Catalysts | Date | Event | Stocks Affected | | --- | --- | --- | | **Apr 18–19** | AACR Annual Meeting, oncology data presentations | Biotech broadly, RVMD | | **Late April** | PDUFA reauthorization expected | Biotech broadly | | **Apr 29** | AbbVie Q1 earnings | ABBV | | **Apr 29–30** | Novo Nordisk & Eli Lilly earnings, GLP-1 revenue trajectory and oral launch uptake | NVO, LLY | | **End of April** | CBER Chief Vinay Prasad departs (no replacement announced) | FDA-dependent biotechs | | **Q2 2026** | Foundayo Type 2 diabetes FDA submission (Commissioner's Priority Review) | LLY | | **Q2 2026** | Stoke Therapeutics (STOK) Phase 3 enrollment completion for Dravet syndrome | STOK | | **July 1** | Medicare GLP-1 Bridge program launch ($50/month copay for Wegovy/Zepbound) | LLY, NVO | | **July 2026** | FDA advisory committee meeting on peptide reclassification (7 peptides) | HIMS, LFMD | | **July 31** | Pharma tariffs take effect | Broad pharma | | **Dec 8** | J&J Enterprise Business Review | JNJ | | **Ongoing** | Revolution Medicines potential accelerated FDA approval | RVMD | | **Ongoing** | Foundayo real-world post-marketing liver safety monitoring | LLY | | **Ongoing** | AbbVie 340B lawsuit against HRSA (multi-year timeline) | ABBV | --- ## 8. The Bottom Line This was one of the most consequential weeks for healthcare in 2026. The GLP-1 oral war is now live, with Foundayo's convenience advantage and aggressive pricing ($149/month) squaring off against oral Wegovy's superior efficacy (16% vs. 11% weight loss). The ACHIEVE-4 cardiovascular data, showing a 57% lower risk of all-cause death and no liver safety signal, is a significant de-risking event for Lilly, though post-marketing surveillance will take months to fully resolve the hepatotoxicity question. The managed care sector got breathing room from MA rates, but the ACA enrollment cracks (14% non-payment, rising uncompensated care) suggest the payer landscape remains treacherous. M&A at a potentially record-setting $172B annual pace is reshaping the sector in real time, with Gilead's three-deal oncology blitz and mid-tier biotechs emerging as acquirers being the most structurally significant developments. For healthcare investors, the message this week is clear: the sector is bifurcated. Large-cap managed care is fighting for margin stability in a politically exposed business; biotech is in a secular bull run driven by innovation maturation and M&A demand; and GLP-1 manufacturers are in a competitive land grab where convenience, pricing, and safety will determine the winners. Choose your sub-sector carefully. --- ```request-access variant: inline heading: Want this kind of synthesis on your own coverage? buttonText: Request access ``` ## Data Gaps and Limitations - **ETF-level news (XLV, XBI):** MFNews returned no results for these tickers; ETF-level commentary sourced from podcasts and web searches instead. - **MRK, AMGN, ABBV, BMY:** Limited ticker-specific news flow this week; coverage primarily from analyst price target adjustments and broader sector commentary. - **Podcast coverage inherently skews toward higher-profile names** (LLY, NVO, UNH, JNJ, GILD), smaller healthcare names may have significant developments not captured. - **Analyst consensus estimates and price targets** referenced herein are sourced from news reports and podcast commentary; we do not have direct access to consensus databases. - **Humana (HUM) and HCA** debates were sourced primarily from web search results rather than direct podcast commentary this week. --- ## Sources - [Insightful Investor](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiB3wOybZr7uTJBLWtNSOkxDzlEa96YLa1uuVTpwHilUIODPV4T-2BO8piI-2BsK-2ByAwjY4CGwvBb7PgGpErlbegtpTsZl-2BTyqt242-2BNRDiWHMX2g-3D-3D2AjE_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V6FJdVR2DbwIPwiMqAAZ7l5-2FHKnTdKU5XpUrgzL9-2FtsGIoUr-2FclbEn0kuC-2FHekrz9ZOWHRZa4YCzPdk0HQqBxfJH9BI55z-2FS308LV-2FqPPpGFRtxV5faUhiizgivxfbKwxw-3D-3D) - [The Real Eisman Playbook](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjc5aPP6aH0J2G9y-2BwxdUivHOac4HNctw3sRmMUBrkwC7oWRtR3eqJIJtRaSmNxmBcb27YHFM9yLZivb7-2BsJAeHvsrH8LaQDOEZPIwMSheupA-3D-3DQavT_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V9BEd76sI0GIuROCZwrtsn16O2zmNdXIM8FGEdbbUHSePR0v9FMyEXnBtbl7vLn3qoGEe91Hp4e0DBl8z8SyBRS0bWYNf5TfRXJJL1f23gLNjmZMjgzI1TtVnv6Z0oNh7w-3D-3D) - [Biotech Hangout](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOj8LUgqyKPHfA5-2By75OCa71nfCnkMjc3W2I9-2ByENTnY8dVyVWvV4y-2Bx98Y2HMidFb0ToBFj5s-2BerV3ebqnNv7AW79CiCQwIHsOXn-2F-2Bfg26xZw-3D-3D9tRo_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V-2FR6SrRw5MHD4pX1IAsLD4rbMDgBvq7fXdQ-2BOpgScy8hLOsXEsWA2G6FDh8EJ2ByS1fxZmBNxZ4etBwTvizDbSm2Ocv3vTv2tUOHDspj81A2Blkcu-2FzhVAKYr5odztWMQg-3D-3D) - [On The Pen](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOheYuA4-2FEGhQw4KFzbCVPwjksu6n8NNuaG01HZ4oJFHqBk6wbQFXFarFbiJeuO7gjrwEAxrsJLCUIKCG5h9MBDMpruxP1NntALdtkLEVKy5dQ-3D-3DWPAl_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31VxJ4-2F-2BFKZo91aFPsFJfwYXV5sw3xYqZy9SE9yujggzu-2B6BpbkfgUDhds5-2BISK-2BxaDHdlat0bqScFccFzkSb-2BeEGD5Dz9mly-2FlBIoY0QLnKlaqS3kH-2BaO2pJXe5SaYLPECQ-3D-3D) - [Bloomberg Intelligence](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhTTvjZqtdAHZPa3E1IEg3ZexpOnQ3HA75hrjBcyc4N1mv9QCK8FQoYw2TZY5ab3GZMoM2BcnVy-2BlkMh-2FKRIL-2B9C3dzEW7w065S4pa4GUJpPw-3D-3DjUWr_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V4B4VhpUcwsQcOQhqXJRLWmRUSbqq6pfvgzkDqYbMOWo8ZkvuDhGmvCckXd7u17gC-2FDHimOnAcoZ4kxv-2Fk8NtrZ-2BDHpq9fI-2BjbF44IAlMTT-2BnoSvXUDvOJbpruLXe4PsjQ-3D-3D) - [Capital Ideas](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjc8kmw0JDFHUpCddxu1V9An14Lu-2FVM-2FpGb6ClE-2BJHum27D2J08B1ObVrlsTXdFw-2FtdY8WUwywtYBIyBzKqS2q3j533vo2dQ5F72BKV0PTRCw-3D-3D5CN9_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V7WrGwL7Oex1kdmOT3gEK-2Fn8uzBnO93rc5qLB01fa3AhJLCib5EUz-2BP00hqguWaHzDDR1JUOLb6kvZF4I3FLK6zC-2BAGeZWDmRTMVXc5sc2Y7WXhtYivn5ceVqa-2BqYfkMaQ-3D-3D) - [Chit Chat Stocks](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOihouZChik-2FmXA2GUPMxE7S5MAojkeJKp1J0hk7dr3Try5c7Q89wk-2FlI3xmu70JPEg-2BcBfAnJr27zfSPsfjU-2F8P0yMZqQApVNZa20UGqFDUfA-3D-3DpT6t_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31Vw2Rz2-2BWxNdxrqYTgvRdgKnF7OYzMoAKwUZNbBqprA5qMBW8SzvlOTeK0XEgwP9altC6jy-2Ft-2BoM0TgfvUhuP-2BdERCg-2BxJbGsEpG0WCwR1DALhtK-2B85eBrmifHk-2BiKjcZrQ-3D-3D) - [Diabetes Dialogue](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOie1E-2BSjDS0W1ChktOp61g4VFZC4kFtVqeOZTL-2BafhHZqS27owz5RL1um5Aa61GEC2VDpVGhCdOWazq9cslsG3Tn5SAMNJxoHdP452ObJWX2Q-3D-3D43Rb_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V-2F9Mcqtc-2FDMbY8K1uOA3FF-2BPtVRJnhSuM6JbL3t2AFe8ovhTCpiPGvmvEP8SY43GtHTCi-2BCXRys1wzuFRGcINZSF7YcisiDxWquc5axOc6blKe0bWqx3FlDTqPSjKiGUPw-3D-3D) - [BioSpace](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhzOs0FIhw2yH3NUAiAy5Yb-2BQhLr172QlwxFrhRMd0fHs1VxNfsBO6wwup6yQP3YKkfMReTiRgOWX9Z4GxOzbF0shlWYN-2BUYtQKVpS0YlAIOg-3D-3DbNNE_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31Vz2-2BK5W7L685eMPZ9tAWsMUPzjRzd0vPqgEa3y-2FCfVWemxvFs-2FiRmVT1K7fs7DfeX26fdCdNp5N3sYxN-2FwNepZL9X-2B5JyAFwN2lDnGq5bxHn4euQmLAKPogEXzKh0p1Q-2Bg-3D-3D) - [Back on Track](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOh34wbyiLvERObxVAsaVC-2FHXndgy4PmPJxtrxyqVdtxKh55JHoN3pshqUHjZxNgQfHExOQ-2FUVgd1ogqjs3v5KdPA7LARvBtAmfK3IcOVGCHxA-3D-3DvRcO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V9K7qjl2B3rRniTCNCmdCgHXfokgr7TTjN-2FZ1mXEk43SKg-2BrjgCUZZW2Ccg4eKxFsZprWCXXN6XHEO-2FKGS83ciFmgC3NgLcl1Uw8VJSIybJi-2Bj6jvRqcnlWi3IL9hpF3hA-3D-3D) - [Weight and Healthcare](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhUFU2HW2zH7b108iRNrcFnR-2Fvd2gHfFWjFOklLDndwF-2Bgf8bEucDBfpSl3SW0gfDP336tvnWZL3p9RuCqdj87V6ZRMKrryU15zS78bwcBwhw-3D-3DKDQ__7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V5K3c9glqXg6vmZsAPsZJhs4Gz8-2FrctqJyecr-2F8XldU9aRMLVaVu3BEDMlXWHiWVRWDxHtbWcG-2B9HMTVxh7Sk7cXIQmCYzjD-2FFvId8P9vgk0F9O3AzZEHMHf9C7Tt7bLFA-3D-3D) - [Best Stocks Now](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhAEG6BvlMvVVv3XpQUiPTpddkwUP-2Bc1GRdWiDa8RFtfuLzbzS-2Bk0SrIJ-2F78fr9z2mX1j5RkkLhRfpi7uphUTB8r5XHn1KPKQ2UEvypZ6v54g-3D-3DXcmD_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V95Idb292M6BGWgmeObVYrGaLiZLse92cD9JzeRzH5e9pgMR5lthYl9ph2pUe1yPIICGnHdWC-2B5-2BkDtPC1bZhFjLqKi-2FRZCUToBbAXb-2Ba0VCPCDUBU2kYbD999G-2FvMSvRg-3D-3D) - [Telltales](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOiPoBbvuJeEZIhq1mC2FSOWW9wDCgR5CU3-2F1NbIVp3nTntEnM5BDL4RdGkGSx4mj-2FcxMiTI00PX0i5EOO5dTCgDyn8HUs10VYGWvmvHko8aQw-3D-3DAsN-_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V5TEuiIONGby0Y33iGNh7PKanx8c1BYzfEGXlqcpmSlzQ-2FMOzA5RYThwb4Rv1EyhOz8AqvF01m84tx7qFzU4jhEkQtHyY-2B-2BWuXkEq-2F-2F8koNkekyiWblOKNE4pZ64-2Bymc2g-3D-3D) - [Squawk on the Street](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgY-2Fd6pnXe7pNqNNqLjTy18Cpj06rtEccba1hWDq-2B5Y7npQTfAKqa78FQbZKEoIMoIuhYVfcdv-2BFC4YJHvILm-2FgDeCLggkccXOYtiqsyoBu8w-3D-3DUp1r_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V8MQw43H0UvfQkPGtPc3DPeT0PB235tb2sVGGOHm-2BIOXa4iqKLs-2BX9IcTG-2FAf5zRJ5DZcA9dInkIRrJRN2P5VqgcmTkpxEWek6fVZRITAtX8I0kRiGbyH8p2FCnDCO-2BP9w-3D-3D) - [A Health Podyssey](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOg-2F-2B5lPXXPzTD8r3kpi8f7hVIr-2FnhPcW7Gd3a-2F6oqlMO5CvBMIzJS4SwIRHLaxlg-2FSeZt3863iezB4nFh14oYIuZHaB-2Fno3je17h8XC-2FQg16Q-3D-3Dey3s_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31Vx6ehoD572eToYyzsG4E7pr2eAR4-2BmllLD-2FP2GuOmcB-2Ft850Hly-2FfFDuO7FFGvUSnnZ-2FvIomU-2B673xYhhufBzNKDsl3BAIcj0te70S8jqAxXrr5emes0WHCGf5ES0dCWUA-3D-3D) - [Achieving Health](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgW-2Bs206ohRco2P1NQ3y8mrKFZDPHD9SmVjH-2BDwGwvLPleVDIr2LDMZA7-2BOsjtc8o3lRMMO3IZOki-2FqRl-2BVlSbO8sq0F2ecwDVfK59KwOfHww-3D-3DCYtd_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V-2BPTVoo2qfzuqKGu1xIMmXHncqNf55s9mubQn5xAz1cMXQXzfy0scwF745qvDtgLogoq9RUqUO56VDmi3VxXXwFJ8YV2-2FKTyQ0bYQLYqbUx1YFQLduuF-2BmJueXRFByTIFQ-3D-3D) - [BioCentury](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgUop0i5ya8KJoMZaGAhtcjoZA6GPfkrWKf3rg82pFCW3aSwTxjBI8n6mxZ79pJbvm2QsIMl3q4LDfKLR3YROpmGX9PEc3gjA3-2FPj19TV-2BKTQ-3D-3DxwKd_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V-2FrsCwfZy538vOnzYsy1WmTj4pZK0yy0KVK26SJKrTsOsdepHuofTnsSegyLa-2BXiHPsWT73F1trHzXCkmrDkSPcrvJlAV2xf-2BpL1q1kmcDsbBvigOkNG-2FNFvJyzDV7Jpdg-3D-3D) - [The Readout Loud](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOia8DH7mFByxAR-2Bw4zVpA3sTsCGiN9rofl9a5y0ddhAfnFmQPMBNvRHd7hFblxJQYnC96Fz1bmD5yDDn9ZHXObCoYLJbU6KlqITzWElhjH2FA-3D-3DkcmT_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31VygnZBgZtlYnvam-2BfsGqk4EU648uOxuKa-2Fj9VWAs988408ZaR2WjXw2uX-2FOO0uA0dUwLn7dL0Fsts5gB-2FRS70rAXq8pepg5mtaGC5ltfUpwj9tdoP7vDvoPctKVk9GAYSw-3D-3D) - [Off Script](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgxzH1dESpuj7aji3gj-2FWPUWqss74w-2BKbq4gCPO14YoVYL7Z4m0Xsw57MmDO-2B1lB-2FVjro6Xqof9cqyrxZZlaFJOJ4HHxUoYQJ55x0FT0-2FxY6A-3D-3DmoHR_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V1-2BMDIAvbkruGnBNAd-2F-2F14dRSmmXmaEL6QsJ8duJOIOUhWEwDu5zQncKFj5VW7RiBAdBxnQFCUQ6obJK9IzIsjYY1glC-2FKSu-2F0P0o0zDjRDqrNdgqlV1tU41BsOdRlJlAQ-3D-3D) - [Health:Further](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjew3rLELzsFTSEQ0YAdWrLOAF13x-2Bo-2B1N-2BDdS9hAzolPeBaSVInOtjVYvjae42iko5gWqqu6XqXDULtAk6kCY8GAJZkXsrLAG4rp69SHUrQw-3D-3DD2KH_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31VzPkhLWw1A540Q1yBF-2BT2y9XUmM7S7CcK7k-2B415VTtKPK6V6aWqVxsEQeRYVOkQhup0-2FvGkVXYLy1uWQqGXZz6p073ro8GG4ElRbzvhPTXV8y3NjLpeOBk85dXyQyfCdrw-3D-3D) - [ChatGPT Podcast](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOjdTHuyq15nimMuBbSxM1CClPThmYfA2arQPtcHoh0QJWSy4dWcgaoNcjIDcryFQblx-2B7EmAbPsQUDFRyMggHsNG9qyglR7fwsUMGMkKGkOvQ-3D-3D4Bl5_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V5vbExD6KdYVcA1aXcH6sSHf1E6l7Pe2e50UZob1QqZ9zsInsoRkhgKC53gV-2BbY4y-2FwR8w1AHG6dW-2FdEiz0kZQlU4QvRIjYB8WnogCQ12Op0hhjn9GlMxwaNd2QW5oXAfA-3D-3D) - [Vital Health Podcast](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhdA75VzyhmbdIlc-2Bt8RXEod-2Bbjegb3cSv5PcDLJ1wPjEC8mrE-2F-2B4hASReXsN8t1aebtTS3CM7GQ4VItKQ6zVtaUsL6TyUwAR9LjRCzkezeew-3D-3D_YLc_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V2w-2FHOtZn-2FVwsHfGGPIrDU5lPTc-2Bj7XKxCYUtINccgUeyROqMV5UYfwr4PkrpldyQCmu3WwJayY7PdMEkNi2xixCBBiQhyCT3s-2FA-2Bp5eHCGX2I5ngVKg8abgnhurWZ2jYw-3D-3D) - [GLP-1 Studio](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOh-2BkFs6T6wPnp2nYpqt01a4Q-2FXi-2BicPCGc9ONeKViwklrSN-2FEGlxbeQDhd0b1VnX0owPghVeecl4M8trh-2BKMGaqeN5zwO4Rkd0Rcf7XcYJ8Pw-3D-3DHemw_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V48kNOy08mpeDSfQoQkZD3ogXqdQD6xBJbx8C3oXNg2d-2F87kv5dqe0UnkYF-2BALn4Ndd2ziMfo7wOkl1PKJ2xq8eCfExHmDyot8-2FkX5kXCchO1vM1WTIj0k4waXGFrcNVfg-3D-3D) - [Keen On America](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOhKRbkoa-2FqhPf2mwA5-2FCZRt9oJaGTKKd-2BFP0w47-2F0vfoMQJLIY2RC9DFmylrrh2WnP3Omw9XS2Mp2YOfk8Nk4g4LboUWBAMuJN7q8h7wpa8GA-3D-3DwlaO_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31VyDELesb8I5ll-2BHGUwuLhHhbidT8i-2BQ2sAMHLH8-2FM0nZyH9ftVUHLClAbFikbneEQaFI4MvHM17H0k4KQMu8mQOnQh5mEyhkV61-2B8mMMPeRc-2BQ7H35LB6DnsWw0KUq80PA-3D-3D) - [Gist Healthcare](http://url7324.matterfact.com/ls/click?upn=u001.idHmPrr2Geh7KYLAsTy7NkrIVb-2FgA4pmf2rMXQwGcOgkqWebEqLP8O-2BBSdOHwlnOfYfPvWFRmRRensLSARfFeoeGMrvc68DBa0bD6OxYiIlWzJlVWRygBmX7FRCxQED3OGQFijYAh-2B9SyTTjhlX6jg-3D-3D82IU_7mLGwmUci-2BLaXswv9WX1yTgqn3Wad-2FotHhzHgSNAZbUgmY3vdeSigYsS1DFL-2Bg2E9USvskhp5aJpzOTV3E31V4HSey3pjfFkhF8J-2Fso7HpsCRup6EInBsPRqS-2BOK-2BTOj1QULhuQa1-2F370trSHwp4FhTtFGSwr-2BTWE0y81f7X-2FwbbGyU9m9m7W7Gs6vM9C5ZMbMER-2FVDtdkw7E9UCJBplzA-3D-3D) ```request-access variant: banner heading: Run your own corpus. description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage. buttonText: Request access ```